(Q38268453)

1 September 2017

1 reference

title

The emerging quest for the optimal angiostatic combination therapy (English)

1 reference

1 September 2017

1

Arjan W Griffioen

1 reference

1 September 2017

Patrycja Nowak-Sliwinska

6

object named as

Patrycja Nowak-Sliwinska

1 reference

1 September 2017

Andrea Weiss

2

1 reference

1 September 2017

Robert H Berndsen

3

1 reference

1 September 2017

U Kulsoom Abdul

4

1 reference

1 September 2017

Marije T te Winkel

5

1 reference

1 September 2017

1 December 2014

1 reference

Biochemical Society Transactions

1 September 2017

1 reference

1 September 2017

42

1 reference

1 September 2017

6

1 reference

1 September 2017

1608-1615

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 September 2017

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

A phase I study of sunitinib plus bevacizumab in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Toxicity of sunitinib plus bevacizumab in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Combining angiogenesis inhibition and radiotherapy: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Metronomics: towards personalized chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Angiostatic activity of the antitumor cytokine interleukin-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

IL-4 reduces the proangiogenic capacity of macrophages by down-regulating HIF-1α translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Interleukin-21 has activity in patients with metastatic melanoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Photodynamic therapy of cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Photodynamic therapy in dermatology: state-of-the-art

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Photodynamic therapy of early squamous cell carcinomas of the esophagus: a review of 31 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Photodynamic therapy for polypoidal choroidal vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Photodiagnosis and photodynamic therapy of peritoneal metastasis of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Photodynamic therapeutic effect of indocyanine green entrapped in polymeric nanoparticles and their anti-EGFR-conjugate in skin cancer in CD1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

Quantitative model for efficient temporal targeting of tumor cells and neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140193

21 January 2018

Identifiers

DOI

10.1042/BST20140193

1 reference

1 September 2017

1 reference